Е.П. Павликова
Lomonosov Moscow State University · 87 works · 557 citations · h-index 8
Top works
- AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
- Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan ( LCZ 696) in Patients with Heart Failure and Reduced Ejection Fraction
- Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study)
- Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study
- Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)”
- Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)
- Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT)
- Mediastinal Emphysema as a Specific Complication of COVID-19 (Case Report)
- Clinical manifestations and outcomes of Fabry disease in 150 adult patients
- Natriuretic peptide inhibition in the presence of angioten-sin receptor blockade following short-term treatment with LCZ 696 in heart failure patients: effect on ANP, BNP, NT-proBNP and cGMP
- Abstract 19378: First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure
- First Experience of Clinical Application of LCZ696 – an AT1-angiotensin Receptors and Neprilysin Inhibitor – in Patients With Chronic Heart Failure and Reduced Ejection Fraction
- Functional assessment of coronary blood flow as contemporary method for optimizing results of percutaneous coronary interventions in patients with ischemic heart disease
- RANDOMIZED COMPARISON OF TWO APPROACHES TO WARFARIN DOSAGE IN CARDIOVASCULAR HOSPITAL SECTION
- Possible role of anti-IL17 drugs in the management of COVID-19: our own experience and literature review
- Liver involvement in patients with systemic lupus erythematosus
- Methods for assessing the quality of pharmacotherapy as tools for improving the effectiveness and safety of treatment interventions
- Prevention of type 2 diabetes in patients with chronic heart failure
- End-stage renal disease in patients with Fabry disease
- Comparative in-vivo and in-vitro study of blood rheological properties in patients with coronary heart disease with laser-optic techniques